Sanjivani Paranteral Ltd — Updates, 27-05-2025: Company Update

Sanjivani Paranteral Ltd has announced a board meeting on which it reported a 41.3% YoY revenue growth to INR 181.8 mn for the quarter, driven by injectables and oral segments. EBITDA margin was at 16.8%, slightly down by 42bps, while PAT surged 74.4% to INR 21.9 mn. For the year, revenue rose 28.8% to INR 701.0 mn, with EBITDA margin improving to 16.5% and PAT increasing 31.4% to INR 81.0 mn. Strong growth in oral products (+63%) and nutraceuticals (+564%) supported overall performance, with 81.5% of revenue from core international markets including CIS, Middle East, Africa, and Latin America.